SomnoMed Full Year 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 09/01/2025 03:10

SomnoMed (ASX:SOM) Full Year 2025 Results

Key Financial Results

  • Revenue: AU$111.5m (up 22% from FY 2024).
  • Net loss: AU$3.46m (loss narrowed by 72% from FY 2024).
  • AU$0.016 loss per share (improved from AU$0.10 loss in FY 2024).
revenue-and-expenses-breakdown
ASX:SOM Revenue and Expenses Breakdown September 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

SomnoMed Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates.

The primary driver behind last 12 months revenue was the Europe segment contributing a total revenue of AU$62.7m (56% of total revenue). The largest operating expense was General & Administrative costs, amounting to AU$38.4m (55% of total expenses). Explore how SOM's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.

Performance of the Australian Medical Equipment industry.

The company's shares are up 8.9% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on SomnoMed's balance sheet.